Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | GALR1 | P47211 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9716896 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9716828 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9716945 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9716944 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9716966 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9716973 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9717020 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL7075139 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9716987 | 0.84 | CYP1A2 (0.62) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9716943 | 0.84 | CYP1A2 (0.62) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098005-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-10 | — | — | WO | claimed |
| US-20240148833-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-09 | — | — | US | claimed |
| US-20230302021-A1 | COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | claimed |
| WO-2023183843-A1 | COMBINATION THERAPY FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | PURDUE RESEARCH FOUNDATION | 2023-09-14 | — | — | US | claimed |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | claimed |
| WO-1992009561-A1 | NEW AMIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-06-11 | — | — | WO | claimed |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | EFIL BIOSCIENCE INC (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12257217-B2 | Compositions and methods for treating hyperphagia in prader-willi syndrome | PURDUE RESEARCH FOUNDATION (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2005051298-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050118226-A1 | Sustained-release implant releases ACAT inhibitor for a time effective to reduce ACAT activity; Alzheimer's disease, atherosclerosis; amyloid- beta reduction | GENERAL HOSPITAL CORPORATION, THE | 2005-06-02 | — | — | US | disclosed |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1493448-A1 | MEDICINAL COMPOSITION COMPRISING ACAT INHIBITOR AND INSULINE RESISTANCE IMPROVING AGENT | Sankyo Company, Limited (JP) | 2005-01-05 | — | — | EP | disclosed |
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1421953-A1 | MEDICINAL COMPOSITIONS CONTAINING ANGIOTENSIN II RECEPTOR ANTAGONIST | Sankyo Company, Limited (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | AGTR2, AGTR1, AGT | SMN1; SMN2 4328/4885CYP1A2 1639/4885CYP2D6 2211/4885 |
| US-12257217-B2 | Compositions and methods for treating hyperphagia in prader-willi syndrome | ACAT2, ACAT1, LCAT | SMN1; SMN2 1603/4885CYP1A2 2085/4885CYP2D6 2822/4885 |
| US-12274681-B2 | Compositions and methods for reducing skin fat | ACAT1, ACAT2, ACACA | SMN1; SMN2 4231/4885CYP1A2 808/4885CYP2D6 2090/4885 |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | ACAT2, ACAT1, LCAT | SMN1; SMN2 2808/4885CYP1A2 1141/4885CYP2D6 1933/4885 |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | ACAT2, ACAT1, ACACA | SMN1; SMN2 3747/4885CYP1A2 2109/4885CYP2D6 3254/4885 |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | ACAT2, ACAT1, LCAT | SMN1; SMN2 3921/4885CYP1A2 1183/4885CYP2D6 2956/4885 |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | ACAT2, ACAT1, LCAT | SMN1; SMN2 3921/4885CYP1A2 1183/4885CYP2D6 2956/4885 |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | GLP1R, GPR119, FABP4 | SMN1; SMN2 3223/4885CYP1A2 2679/4885CYP2D6 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.